Asked by: Anneliese Dodds (Labour (Co-op) - Oxford East)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps he is taking to assess the need for the provision of the vaccination against Covid for (a) children and (b) adults who are suffers of Long-Covid.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
I refer the Hon. Member to the answer I gave on 2 February 2026 to Question 108759.
Asked by: Anneliese Dodds (Labour (Co-op) - Oxford East)
Question to the Foreign, Commonwealth & Development Office:
To ask the Secretary of State for Foreign, Commonwealth and Development Affairs, what representations she has made to her international counterparts on the protection of Kurdish civilians in Northern areas of Syria, in the context of reported ceasefire violations in Syria.
Answered by Hamish Falconer - Parliamentary Under-Secretary (Foreign, Commonwealth and Development Office)
I refer the Hon Member to the Written Ministerial Statement I made to the House on 28 January 2026.
Asked by: Anneliese Dodds (Labour (Co-op) - Oxford East)
Question to the Foreign, Commonwealth & Development Office:
To ask the Secretary of State for Foreign, Commonwealth and Development Affairs, what representations she has made to her international counterparts on the protection of (a) Kurdish, (b) Yezidi and (c) Christian communities.
Answered by Hamish Falconer - Parliamentary Under-Secretary (Foreign, Commonwealth and Development Office)
I refer the Hon Member to the Written Ministerial Statement I made to the House on 28 January 2026.
Asked by: Anneliese Dodds (Labour (Co-op) - Oxford East)
Question to the Foreign, Commonwealth & Development Office:
To ask the Secretary of State for Foreign, Commonwealth and Development Affairs, what representations she has made to her Syrian counterpart on the protection of Kurdish civilians in northern areas of that country.
Answered by Hamish Falconer - Parliamentary Under-Secretary (Foreign, Commonwealth and Development Office)
I refer the Hon Member to the Written Ministerial Statement I made to the House on 28 January 2026.
Asked by: Anneliese Dodds (Labour (Co-op) - Oxford East)
Question to the Foreign, Commonwealth & Development Office:
To ask the Secretary of State for Foreign, Commonwealth and Development Affairs, what recent assessment she has made of the potential merits of providing humanitarian assistance in Syria in the context of reports of ceasefire violations in the region.
Answered by Hamish Falconer - Parliamentary Under-Secretary (Foreign, Commonwealth and Development Office)
I refer the Hon Member to the Written Ministerial Statement I made to the House on 28 January 2026.
Asked by: Anneliese Dodds (Labour (Co-op) - Oxford East)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment he has made of the adequacy of the National Institute for Health and Care Excellence (NICE)'s current Highly Specialised Technologies Guidance, specifically where it does not recommend a treatment for a rare disease where treatment would have a substantial effect of a medicine on quality and length of life, but is not recommended due to cost-effectiveness estimates being higher than what NICE usually considers an acceptable use of NHS resources for Highly Specialised Technologies.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
The National Institute for Health and Care Excellence (NICE) operates a separate Highly Specialised Technologies (HST) programme to evaluate a very small number of medicines and treatments developed for ultra‑rare, severe and life‑limiting conditions. It uses specific methods and a much higher cost‑effectiveness threshold than standard technology appraisals, enabling NICE to recommend treatments at prices that reflect the complexities of ultra‑rare diseases. The HST programme has secured access for National Health Service patients with very rare diseases to effective treatments that NICE would not have been able to recommend through its standard technology appraisal process, with 33 out of the 35 medicines that it has evaluated through the HST programme recommended for NHS use.
There will unfortunately always be occasions when NICE is unable to recommend a treatment through the HST programme despite the use of a much higher cost-effectiveness threshold. These are very difficult decisions to make, and it is right that they are taken independently and on the basis of a thorough assessment of the available evidence.
Asked by: Anneliese Dodds (Labour (Co-op) - Oxford East)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what discussions he has had with NHS England, the National Institute for Health and Care Excellence and the Medicines and Healthcare products Regulatory Agency on the annual meeting held to discuss progress and the role of the Early Access to Medicines Scheme, the Innovative Licensing and Access Pathway and the Innovative Medicines Fund in supporting access to treatments for people living with rare diseases.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
The Government is committed to improving the lives of people living with rare diseases through the UK Rare Diseases Framework. One of the priorities of the framework is improving access to specialist care, treatment, and drugs.
We have continued to review the effectiveness of the Early Access to Medicines Scheme, the Innovative Licensing and Access Pathway, and the Innovative Medicines Fund. These access pathways across the regulatory and access system are designed to support innovative treatments being made available earlier to patients who need them, including people living with rare diseases. The last meeting was held in July 2025, and included representatives from the Department, NHS England, the National Institute for Health and Care Excellence, and the Medicines and Healthcare products Regulatory Agency, as well as patient advocacy groups, industry, and clinical researchers. Further detail will be reported in the England 2026 Rare Diseases Action Plan, to be published in spring 2026.
Asked by: Anneliese Dodds (Labour (Co-op) - Oxford East)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment has he made of the potential merits of increasing NICE's cost-effectiveness thresholds used to evaluate Highly Specialised Technologies for rare diseases.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
There are currently no plans to increase the cost‑effectiveness threshold for the highly specialised technologies (HST) programme. The HST programme already operates at a much higher threshold than standard National Institute for Health and Care Excellence (NICE) technology appraisals, reflecting the challenges of bringing treatments for very rare conditions to market, and NICE has been able to recommend nearly all the treatments that have been evaluated through the HST programme for National Health Service use.
Asked by: Anneliese Dodds (Labour (Co-op) - Oxford East)
Question to the Department for Education:
To ask the Secretary of State for Education, how many and what percentage of undergraduate students who are parents with caring responsibilities receive the Childcare Grant.
Answered by Josh MacAlister - Parliamentary Under-Secretary (Department for Education)
The number of full-time undergraduates domiciled in England who received the Childcare Grant in 2024/25 was 42,900, rounded to the nearest hundred. This is published here: https://www.gov.uk/government/statistics/student-support-for-higher-education-in-england-2025/student-support-for-higher-education-in-england-2025#childcare-grant
It is not possible to report this as a percentage of parents with caring responsibilities as the department does not hold the total number of undergraduates who are parents with caring responsibilities. This is because declaration of caring responsibilities is optional and only required for applicants who wish to apply for Special Support Loans or Childcare Grants.
Asked by: Anneliese Dodds (Labour (Co-op) - Oxford East)
Question to the Department for Environment, Food and Rural Affairs:
To ask the Secretary of State for Environment, Food and Rural Affairs, what assessment she has made of the potential impact of air pollution on different groups by ethnicity.
Answered by Emma Hardy - Parliamentary Under-Secretary (Department for Environment, Food and Rural Affairs)
While air pollution impacts many people’s health, the department recognises that these impacts are not felt equally. This is an issue that Defra takes seriously, which is why the Government commissioned the independent Air Quality Expert Group (AQEG) to examine the evidence on air pollution disparities across different communities and regions in the UK.
Their report demonstrates spatial differences in pollution emissions and concentrations. There is evidence of higher air pollution concentrations being experienced by certain minority ethnicity groups.
The report provides a number of recommendations to address this complex challenge, which the department is now considering and have fed through to commitments in the NHS 10 Year Plan and the Environmental Improvement Plan.